Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Association of megalin genetic polymorphisms with prostate cancer risk and prognosis.

Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA.

Clin Cancer Res. 2008 Jun 15;14(12):3823-31. doi: 10.1158/1078-0432.CCR-07-4566.

2.

CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.

Travis RC, Schumacher F, Hirschhorn JN, Kraft P, Allen NE, Albanes D, Berglund G, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Calle EE, Chanock S, Dunning AM, Hayes R, Feigelson HS, Gaziano JM, Giovannucci E, Haiman CA, Henderson BE, Kaaks R, Kolonel LN, Ma J, Rodriguez L, Riboli E, Stampfer M, Stram DO, Thun MJ, Tjønneland A, Trichopoulos D, Vineis P, Virtamo J, Le Marchand L, Hunter DJ.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2734-44. doi: 10.1158/1055-9965.EPI-09-0496. Epub 2009 Sep 29.

3.

Association of hepsin gene variants with prostate cancer risk and prognosis.

Holt SK, Kwon EM, Lin DW, Ostrander EA, Stanford JL.

Prostate. 2010 Jun 15;70(9):1012-9. doi: 10.1002/pros.21135.

4.

Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Chen YC, Kraft P, Bretsky P, Ketkar S, Hunter DJ, Albanes D, Altshuler D, Andriole G, Berg CD, Boeing H, Burtt N, Bueno-de-Mesquita B, Cann H, Canzian F, Chanock S, Dunning A, Feigelson HS, Freedman M, Gaziano JM, Giovannucci E, Sánchez MJ, Haiman CA, Hallmans G, Hayes RB, Henderson BE, Hirschhorn J, Kaaks R, Key TJ, Kolonel LN, LeMarchand L, Ma J, Overvad K, Palli D, Pharaoh P, Pike M, Riboli E, Rodriguez C, Setiawan VW, Stampfer M, Stram DO, Thomas G, Thun MJ, Travis RC, Virtamo J, Trichopoulou A, Wacholder S, Weinstein SJ.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1973-81.

5.

Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.

Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson JE, Li G, Adami HO, Liu W, Tolin A, Turner AR, Meyers DA, Isaacs WB, Xu J, Grönberg H.

J Natl Cancer Inst. 2005 Apr 6;97(7):525-32.

PMID:
15812078
6.

Genetic variation in the HSD17B1 gene and risk of prostate cancer.

Kraft P, Pharoah P, Chanock SJ, Albanes D, Kolonel LN, Hayes RB, Altshuler D, Andriole G, Berg C, Boeing H, Burtt NP, Bueno-de-Mesquita B, Calle EE, Cann H, Canzian F, Chen YC, Crawford DE, Dunning AM, Feigelson HS, Freedman ML, Gaziano JM, Giovannucci E, Gonzalez CA, Haiman CA, Hallmans G, Henderson BE, Hirschhorn JN, Hunter DJ, Kaaks R, Key T, Le Marchand L, Ma J, Overvad K, Palli D, Pike MC, Riboli E, Rodriguez C, Setiawan WV, Stampfer MJ, Stram DO, Thomas G, Thun MJ, Travis R, Trichopoulou A, Virtamo J, Wacholder S.

PLoS Genet. 2005 Nov;1(5):e68. Epub 2005 Nov 25.

7.

Estrogen receptor beta polymorphism is associated with prostate cancer risk.

Thellenberg-Karlsson C, Lindström S, Malmer B, Wiklund F, Augustsson-Bälter K, Adami HO, Stattin P, Nilsson M, Dahlman-Wright K, Gustafsson JA, Grönberg H.

Clin Cancer Res. 2006 Mar 15;12(6):1936-41.

8.
9.

Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer.

Johansson M, McKay JD, Stattin P, Canzian F, Boillot C, Wiklund F, Adami HO, Bälter K, Grönberg H, Kaaks R.

Int J Cancer. 2007 Feb 1;120(3):539-42.

10.

Vitamin D pathway gene variants and prostate cancer prognosis.

Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z, Ostrander EA, Peters U, Stanford JL.

Prostate. 2010 Sep 15;70(13):1448-60. doi: 10.1002/pros.21180.

11.

IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).

Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossus L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS; Breast and Prostate Cancer Cohort Consortium.

PLoS One. 2008 Jul 2;3(7):e2578. doi: 10.1371/journal.pone.0002578.

12.

Single nucleotide polymorphisms in DKK3 gene are associated with prostate cancer risk and progression.

Kim MS, Lee HN, Kim HJ, Myung SC.

Int Braz J Urol. 2015 Sep-Oct;41(5):869-97. doi: 10.1590/S1677-5538.IBJU.2014.0041.

13.

Prostate cancer susceptibility variants confer increased risk of disease progression.

Cheng I, Plummer SJ, Neslund-Dudas C, Klein EA, Casey G, Rybicki BA, Witte JS.

Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2124-32. doi: 10.1158/1055-9965.EPI-10-0268. Epub 2010 Jul 22.

14.

The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy.

Laverdière I, Flageole C, Audet-Walsh É, Caron P, Fradet Y, Lacombe L, Lévesque É, Guillemette C.

Endocr Relat Cancer. 2015 Feb;22(1):77-85. doi: 10.1530/ERC-14-0423. Epub 2014 Dec 1.

15.

The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.

Sun T, Oh WK, Jacobus S, Regan M, Pomerantz M, Freedman ML, Lee GS, Kantoff PW.

Cancer Prev Res (Phila). 2011 Dec;4(12):2044-50. doi: 10.1158/1940-6207.CAPR-11-0283. Epub 2011 Sep 7.

16.

Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk.

Lindmark F, Zheng SL, Wiklund F, Bälter KA, Sun J, Chang B, Hedelin M, Clark J, Johansson JE, Meyers DA, Adami HO, Isaacs W, Grönberg H, Xu J.

Br J Cancer. 2005 Aug 22;93(4):493-7.

17.

Effect of IL-18 gene promoter polymorphisms on prostate cancer occurrence and prognosis in Han Chinese population.

Liu JM, Liu JN, Wei MT, He YZ, Zhou Y, Song XB, Ying BW, Huang J.

Genet Mol Res. 2013 Mar 15;12(1):820-9. doi: 10.4238/2013.March.15.2.

18.

Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival.

Kanda S, Tsuchiya N, Narita S, Inoue T, Huang M, Chiba S, Akihama S, Saito M, Numakura K, Tsuruta H, Satoh S, Saito S, Ohyama C, Arai Y, Ogawa O, Habuchi T.

Int J Cancer. 2015 Jan 1;136(1):74-82. doi: 10.1002/ijc.28952. Epub 2014 May 20.

19.

The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer.

Perez CA, Chen H, Shyr Y, Courtney R, Zheng W, Cai Q, Hwang M, Jaboin J, Schleicher S, Moretti L, Wills M, Smith JA, Lu B.

J Urol. 2010 May;183(5):2062-9. doi: 10.1016/j.juro.2009.12.098. Epub 2010 Mar 19.

20.

Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence.

Ahn J, Kibel AS, Park JY, Rebbeck TR, Rennert H, Stanford JL, Ostrander EA, Chanock S, Wang MH, Mittal RD, Isaacs WB, Platz EA, Hayes RB.

Clin Cancer Res. 2011 Mar 1;17(5):1075-81. doi: 10.1158/1078-0432.CCR-10-0881. Epub 2011 Feb 22.

Supplemental Content

Support Center